Physician profile
Zvi Levran
NPI 1720020068
$1,670.75
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $61.72 · 2021: $1,440 · 2022: $42.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,421.24 | 2020-2022 | |
| Neotract INC. | $63.76 | 2019 | |
| Olympus America INC. | $47.22 | 2019 | |
| Astellas Pharma US INC | $37.58 | 2020 | |
| Myriad Genetic Laboratories, INC. | $32.70 | 2021 | |
| Coloplast Corp | $30.38 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.22 | 2022 | |
| Medtronic USA, INC. | $15.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zvi Levran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.